BB-TME

BB-TME is an investigational small molecule drug candidate developed by Broaden Biopharma (also known as BrodenBio) that is currently in the preclinical stage of development. The agent is specifically designed to target and modulate the tumor microenvironment (TME) for the treatment of solid tumors. The TME is a complex milieu consisting of non-cancerous cells, signaling molecules, and the extracellular matrix that surrounds a tumor, often creating an immunosuppressive environment that facilitates tumor growth and immune evasion. By targeting components within this environment, BB-TME aims to reverse immunosuppression and enhance the therapeutic efficacy of anti-cancer treatments. This program is part of Broaden Biopharma's oncology pipeline, which focuses on developing innovative small molecules for challenging cancer indications.